Serum NfL and GFAP as biomarkers of progressive neurodegeneration in TBI
Alzheimer's & Dementia · 2024
DOI: 10.1002/alz.13898 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2024. Verfasst von Pashtun Shahim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Rehabilitation Medicine Department, National Institutes of Health (NIH) Clinical Center, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Glial Fibrillary Acidic Protein, Neurofilament Proteins, Brain Injuries, Traumatic, Biomarkers. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, Office of the Director, and Uniformed Services University, National Institutes of Health (NIH) Clinical Center.
Abstract (Originalsprache)
BACKGROUND We examined spatial patterns of brain atrophy after mild, moderate, and severe traumatic brain injury (TBI), the relationship between progression of brain atrophy with initial traumatic axonal injury (TAI), cognitive outcome, and with serum biomarkers of brain injury. METHODS A total of 143 patients with TBI and 43 controls were studied cross‐sectionally and longitudinally up to 5 years with multiple assessments, which included brain magnetic resonance imaging, cognitive testing, and serum biomarkers. RESULTS TBI patients showed progressive volume loss regardless of injury severity over several years, and TAI was independently associated with accelerated brain atrophy. Cognitive performance improved over time. Higher baseline serum neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) were associated with greater rate of brain atrophy over 5 years. DISCUSSSION Spatial patterns of atrophy differ by injury severity and TAI is associated with the progression of brain atrophy. Serum NfL and GFAP show promise as non‐invasive prognostic biomarkers of progressive neurodegeneration in TBI. Highlights In this longitudinal study of patient with mild, moderate, and severe traumatic brain injury (TBI) who were assessed with paired magnetic resonance imaging (MRI), blood biomarkers, and cognitive assessments, we found that brain atrophy after TBI is progressive and continues for many years even after a mild head trauma without signs of brain injury on conventional MRI. We found that spatial pattern of brain atrophy differs between mild, moderate, and severe TBI, where in patients with mild TBI , atrophy is mainly seen in the gray matter, while in those with moderate to severe brain injury atrophy is predominantly seen in the subcortical gray matter and whiter matter. Cognitive performance improves over time after a TBI. Serum measures of neurofilament light or glial fibrillary acidic protein are associated with progression of brain atrophy after TBI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rehabilitation Medicine Department, National Institutes of Health (NIH) Clinical Center, Bethesda, Maryland, USA.
- National Institutes of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA.
- Department of Neurology, MedStar Georgetown University Hospital, Pasquerilla Healthcare Center, Washington, District of Columbia, USA.
- The Military Traumatic Brain Injury Initiative (MTBI2), Bethesda, Maryland, USA.
- The Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.
- Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
ORCID-Profile: Pashtun Shahim
Förderung
- NINDS NIH HHS
- Office of the Director, and Uniformed Services University
- National Institutes of Health (NIH) Clinical Center
Zitieren
APA
Shahim, P., Pham, D. L., van der Merwe, A. J., Moore, B., Chou, Y. Y., Lippa, S. M., Kenney, K., Diaz-Arrastia, R., & Chan, L. (2024). Serum NfL and GFAP as biomarkers of progressive neurodegeneration in TBI. Alzheimer's & Dementia. https://doi.org/10.1002/alz.13898
Vancouver
Shahim P, Pham DL, van der Merwe AJ, Moore B, Chou YY, Lippa SM, et al. Serum NfL and GFAP as biomarkers of progressive neurodegeneration in TBI. Alzheimer's & Dementia. 2024. doi:10.1002/alz.13898
BibTeX
@article{Shahim2024,
author = {Shahim, Pashtun and Pham, Dzung L and van der Merwe, Andre J and Moore, Brian and Chou, Yi-Yu and Lippa, Sara M and Kenney, Kimbra and Diaz-Arrastia, Ramon and Chan, Leighton},
title = {Serum NfL and GFAP as biomarkers of progressive neurodegeneration in TBI},
journal = {Alzheimer's & Dementia},
year = {2024},
doi = {10.1002/alz.13898}
}
EUVIMED